See the published version of this preprint at Lipids in Health and Disease.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research
Stefan Zielen
Goethe-Universitat Frankfurt am Main
Corresponding Author
ORCiD: https://orcid.org/0000-0003-1204-0627
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background Many patients suffering from exercise-induced asthma (EIA) have normal lung function at rest and show symptoms and a decline in FEV 1 when they do sports or during exercise-challenge. It has been described that long-chain polyunsaturated fatty acids (LCPUFA) could exert a protective effect on EIA.
Methods In this study the protective effect of supplementation with a special combination of n-3 and n-6 LCPUFA (sc-LCPUFA) (total 1.19 g/ day) were investigated in an EIA cold air provocation model. Primary outcome measure: Decrease in FEV 1 after exercise challenge and secondary outcome measure: anti-inflammatory effects monitored by exhaled NO (eNO) before and after sc-LCPUFA supplementation versus placebo.
Results 99 patients with exercise-induced symptoms aged 10 to 45 were screened by a standardized exercise challenge in a cold air chamber at 4 °C. 73 patients fulfilled the inclusion criteria of a FEV 1 decrease >15% and were treated double-blind placebo-controlled for four weeks either with sc-LCPUFA or placebo. 32 patients in each group completed the study. Mean FEV 1 decrease after cold air exercise challenge and eNO were unchanged after four weeks sc-LCPUFA supplementation.
Conclusion Supplementation with sc-LCPUFA at a dose of 1.19 g/d did not have any broncho-protective ant anti-inflammatory effects on EIA.
Keywords
Exercise-induced asthma, exercise challenge, forced expiratory volume in 1 second, exhaled nitric oxide, long-chain polyunsaturated fatty acids, double-blind placebo-controlled trial
Figure 1
Figure 2
Figure 3
Figure 4
This is a list of supplementary files associated with this preprint. Click to download.
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at Lipids in Health and Disease.
Version 3
Posted 14 May, 2020
No community comments so far
Editor assigned
On 30 Apr, 2020
Editorial decision: Accept
On 30 Apr, 2020
Submission checks complete
On 29 Apr, 2020
Editor invited
On 29 Apr, 2020
No comments provided
Editorial decision: Minor revision
On 15 Apr, 2020
Review #4 received
Received 14 Apr, 2020
Review #2 received
Received 12 Apr, 2020
Review #3 received
Received 11 Apr, 2020
Review #1 received
Received 09 Apr, 2020
Reviewer #4 agreed
On 07 Apr, 2020
Reviewer #3 agreed
On 02 Apr, 2020
Reviewers invited
Invitations sent on 01 Apr, 2020
Reviewer #1 agreed
On 01 Apr, 2020
Reviewer #2 agreed
On 01 Apr, 2020
Editor assigned
On 31 Mar, 2020
Submission checks complete
On 30 Mar, 2020
Editor invited
On 30 Mar, 2020
No comments provided
Review #3 received
Received 12 Feb, 2020
Editorial decision: Major revision
On 12 Feb, 2020
Review #2 received
Received 05 Feb, 2020
Reviewer #3 agreed
On 22 Jan, 2020
Review #1 received
Received 22 Jan, 2020
Reviewer #2 agreed
On 19 Jan, 2020
Reviewer #1 agreed
On 11 Jan, 2020
Reviewers invited
Invitations sent on 10 Jan, 2020
Editor assigned
On 06 Jan, 2020
Submission checks complete
On 05 Jan, 2020
Editor invited
On 05 Jan, 2020
First submitted
On 03 Jan, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
See the published version of this preprint at Lipids in Health and Disease.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research
Stefan Zielen
Goethe-Universitat Frankfurt am Main
Corresponding Author
ORCiD: https://orcid.org/0000-0003-1204-0627
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at Lipids in Health and Disease.
Version 3
Posted 14 May, 2020
No community comments so far
Editor assigned
On 30 Apr, 2020
Editorial decision: Accept
On 30 Apr, 2020
Submission checks complete
On 29 Apr, 2020
Editor invited
On 29 Apr, 2020
No comments provided
Editorial decision: Minor revision
On 15 Apr, 2020
Review #4 received
Received 14 Apr, 2020
Review #2 received
Received 12 Apr, 2020
Review #3 received
Received 11 Apr, 2020
Review #1 received
Received 09 Apr, 2020
Reviewer #4 agreed
On 07 Apr, 2020
Reviewer #3 agreed
On 02 Apr, 2020
Reviewers invited
Invitations sent on 01 Apr, 2020
Reviewer #1 agreed
On 01 Apr, 2020
Reviewer #2 agreed
On 01 Apr, 2020
Editor assigned
On 31 Mar, 2020
Submission checks complete
On 30 Mar, 2020
Editor invited
On 30 Mar, 2020
No comments provided
Review #3 received
Received 12 Feb, 2020
Editorial decision: Major revision
On 12 Feb, 2020
Review #2 received
Received 05 Feb, 2020
Reviewer #3 agreed
On 22 Jan, 2020
Review #1 received
Received 22 Jan, 2020
Reviewer #2 agreed
On 19 Jan, 2020
Reviewer #1 agreed
On 11 Jan, 2020
Reviewers invited
Invitations sent on 10 Jan, 2020
Editor assigned
On 06 Jan, 2020
Submission checks complete
On 05 Jan, 2020
Editor invited
On 05 Jan, 2020
First submitted
On 03 Jan, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at Lipids in Health and Disease.
Background Many patients suffering from exercise-induced asthma (EIA) have normal lung function at rest and show symptoms and a decline in FEV 1 when they do sports or during exercise-challenge. It has been described that long-chain polyunsaturated fatty acids (LCPUFA) could exert a protective effect on EIA.
Methods In this study the protective effect of supplementation with a special combination of n-3 and n-6 LCPUFA (sc-LCPUFA) (total 1.19 g/ day) were investigated in an EIA cold air provocation model. Primary outcome measure: Decrease in FEV 1 after exercise challenge and secondary outcome measure: anti-inflammatory effects monitored by exhaled NO (eNO) before and after sc-LCPUFA supplementation versus placebo.
Results 99 patients with exercise-induced symptoms aged 10 to 45 were screened by a standardized exercise challenge in a cold air chamber at 4 °C. 73 patients fulfilled the inclusion criteria of a FEV 1 decrease >15% and were treated double-blind placebo-controlled for four weeks either with sc-LCPUFA or placebo. 32 patients in each group completed the study. Mean FEV 1 decrease after cold air exercise challenge and eNO were unchanged after four weeks sc-LCPUFA supplementation.
Conclusion Supplementation with sc-LCPUFA at a dose of 1.19 g/d did not have any broncho-protective ant anti-inflammatory effects on EIA.
Figure 1
Figure 2
Figure 3
Figure 4
Loading...